iSpecimen Inc. (NASDAQ:ISPC) Short Interest Up 5.4% in March

iSpecimen Inc. (NASDAQ:ISPC) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 15,700 shares, a growth of 5.4% from the February 29th total of 14,900 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 123,800 shares, the days-to-cover ratio is currently 0.1 days.

iSpecimen Stock Performance

Shares of NASDAQ ISPC opened at $0.24 on Wednesday. iSpecimen has a 52 week low of $0.20 and a 52 week high of $2.05. The stock has a market capitalization of $2.20 million, a P/E ratio of -0.20 and a beta of 1.70. The stock’s fifty day moving average is $0.40 and its 200 day moving average is $0.50.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in shares of iSpecimen during the first quarter worth about $56,000. Citadel Advisors LLC acquired a new position in iSpecimen in the second quarter valued at approximately $33,000. BlackRock Inc. lifted its stake in iSpecimen by 903.6% in the first quarter. BlackRock Inc. now owns 71,175 shares of the company’s stock valued at $382,000 after buying an additional 64,083 shares during the period. Finally, Vanguard Group Inc. lifted its stake in iSpecimen by 166.3% in the third quarter. Vanguard Group Inc. now owns 163,703 shares of the company’s stock valued at $270,000 after buying an additional 102,241 shares during the period. Institutional investors own 13.62% of the company’s stock.

About iSpecimen

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.